Takayuki Naito

This inventor holds 52 USPTO granted patents, primarily in Antibiotic Compounds (CPC class 544 ). Top assignees: Bristol-Myers Company, Bristol-Myers Squibb Compnay. Active years: 1976-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takayuki Naito. Retrieved from https://idiyas.com/inventor/takayuki-naito

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 52

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 341(Granted Patents)

Forward Citations (Not Self Cited) = 313(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Tokyo, JA (1976)
Kawasaki, JA (1978)
Kawasaki, JP (1978 - 1998)

Company Filing History:

43 out of 637

Bristol-Myers Company

patents

9 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 1976-1998

Loading Chart...

Areas of Expertise:

Pradimicin Derivatives

Cephalosporin Compounds

Epipodophyllotoxin

Bronchodilators

Purine Derivatives

Antibacterial Agents

Chemical Modification

Dioxo Piperazine

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5837828 - Pradimicin derivatives (1998-11-17),

2. 5696096 - Pradimicin derivatives (1997-12-09),

3. 5410029 - Pradimicin derivatives (1995-04-25),

4. 5374711 - Chemical modification of 2'-amino group in elsamicin a (1994-12-20),

5. 5237055 - Chemical modification of 2'-amino group in elsamicin A (1993-08-17),

6. 5229371 - Chemical modification of elsamicin A at the 3' and/or 4' OH groups (1993-07-20),

7. 5227370 - Pradimicin derivatives (1993-07-13),

8. 5126336 - Antibiotic C-3 catechol-substituted cephalosporin compounds, (1992-06-30),

9. 5066645 - Epipodophyllotoxin altroside derivatives (1991-11-19),

10. 5036055 - Acylated derivatives of etoposide (1991-07-30),

11. 5034380 - Alkoxymethylidene epipodophyllotoxin glucosides (1991-07-23),

12. 4935508 - Process for cephem prodrug esters (1990-06-19),

13. 4912204 - Fluoro-substituted epipodophyllotoxin glucosides (1990-03-27),

14. 4874856 - 3-(substituted)propenyl-7-(aminothiazolylacetamido) (1989-10-17),

15. 4751295 - Cephalosporin derivatives (1988-06-14),

Title: **Innovative Contributions of Takayuki Naito in Antifungal Research**

Introduction

Takayuki Naito, based in Kawasaki, Japan, is a notable inventor with a remarkable portfolio of 52 patents. His work primarily focuses on developing innovative antifungal agents, demonstrating his significant contributions to the field of pharmaceuticals and medical research.

Latest Patents

Among Naito's latest innovations are novel compounds known as pradimicin derivatives. These patents detail the synthesis of neutral sugar derivatives of pradimicins, highlighting their prospective use as effective antifungal agents. The descriptions within his patents specify new formulations of compounds with the formula ##STR1##, where various groups are modified to enhance efficacy against fungal infections. The compounds include specific sugar moieties such as .beta.-L-xylosyl, .beta.-D-ribosyl, and others—tailored for optimal therapeutic application.

Career Highlights

Naito's career features pivotal roles at prominent pharmaceutical companies, including Bristol-Myers Company and Bristol-Myers Squibb Company. His dedication and ingenuity in this sector have earned him recognition for advancing antifungal therapies through his patented inventions.

Collaborations

Throughout his career, Takayuki Naito has collaborated with other distinguished professionals, such as Jun Okumura and Hajime Kamachi. These partnerships have fostered an environment ripe for innovation, helping bring groundbreaking antifungal compounds from conception to practical application.

Conclusion

Takayuki Naito exemplifies the spirit of innovation in the pharmaceutical industry, with a focus on combating fungal infections through state-of-the-art discoveries. His numerous patents and collaborations demonstrate a commitment to advancing health solutions, paving the way for future developments in antifungal therapies.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]